구조모아 (StructureMoa)항암 chemical structure spider web
방문Regeneron
분석
큐레이션 브리핑
경쟁 포지션: Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
기전. Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA × CD3
Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody
US, EU
Approved
lynozyfic · linvoseltamab · Lynozyfic · REGN5458 · linvoseltamab-gcpt
2026-09-10
Data Confidence · High
Development Signal · Established
CD3 bispecific T-cell engager
Fully human BCMA×CD3 IgG4-based bispecific (Veloci-Bi)
Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen.
구조화 데이터
Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen.
BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy.
CD3 bispecific T-cell engager
BCMA × CD3 · BCMA expression is not a companion diagnostic; soluble BCMA is exploratory.
CRS and ICANS during step-up; infection and hypogammaglobulinemia on the tail
Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
Triple-class-exposed R/R myeloma after ≥4 prior lines
4L+
IV with step-up
Step-up then weekly, with q2w/q4w response-adapted options
ORR ~70%, CR ~45% in LINKER-MM1
CRS and ICANS during step-up; infection and hypogammaglobulinemia on the tail
Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity.
Polyclonal T-cell activation with cytokine release during step-up.
Perforin/granzyme lysis of BCMA+ plasma cells.
BCMA expression is not a companion diagnostic; soluble BCMA is exploratory.
BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy.
구조화 데이터
Human
IgG-like, supporting weekly then less frequent dosing
ORR, MRD, soluble BCMA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (R/R myeloma, 4L+)
APPROVAL · 2025년 7월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Regeneron
분석
큐레이션 브리핑
경쟁 포지션: Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
기전. Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA × CD3
Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody
US, EU
Approved
lynozyfic · linvoseltamab · Lynozyfic · REGN5458 · linvoseltamab-gcpt
2026-09-10
Data Confidence · High
Development Signal · Established
CD3 bispecific T-cell engager
Fully human BCMA×CD3 IgG4-based bispecific (Veloci-Bi)
Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen.
구조화 데이터
Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen.
BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy.
CD3 bispecific T-cell engager
BCMA × CD3 · BCMA expression is not a companion diagnostic; soluble BCMA is exploratory.
CRS and ICANS during step-up; infection and hypogammaglobulinemia on the tail
Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
Triple-class-exposed R/R myeloma after ≥4 prior lines
4L+
IV with step-up
Step-up then weekly, with q2w/q4w response-adapted options
ORR ~70%, CR ~45% in LINKER-MM1
CRS and ICANS during step-up; infection and hypogammaglobulinemia on the tail
Second approved BCMA engager after Tecvayli; dosing frequency is the operational split.
Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity.
Polyclonal T-cell activation with cytokine release during step-up.
Perforin/granzyme lysis of BCMA+ plasma cells.
BCMA expression is not a companion diagnostic; soluble BCMA is exploratory.
BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy.
구조화 데이터
Human
IgG-like, supporting weekly then less frequent dosing
ORR, MRD, soluble BCMA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (R/R myeloma, 4L+)
APPROVAL · 2025년 7월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.